Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

TPB Publications

1995 Abstracts/Presentations

  1. Arneson, D., E. Evans, R. Kovatch, R. Moore, T. Morton, J. Tomaszewski and A.C. Smith, 1995. Preclinical Toxicology and Pharmacology of Flavopiridol (NSC-649890) in Rats and Dogs. [Abstract No. 2181]. Proc. Amer. Assoc. Cancer Res., 36, 366.
  2. Evans, E., D. Arneson, R. Kovatch, J. Supko, T. Morton, L. Siemann, J. Cannon, J. Tomaszewski and A. Smith, 1995. Toxicology and Pharmacology of Perillyl Alcohol (NSC-641066) in Rats and Dogs. [Abstract No. 2180]. Proc. Amer. Assoc. Cancer Res., 36, 366.
  3. Hill, D.L., L.M. Rose, K.F. Tillery, T.-H., Lin and T.-W. Shih, 1995. Disposition of 2'-Deoxycoformycin and Cordycepin in Mice Dosed with These Compounds Singly or in Combination, [Abstract No. 2135]. Proc. Amer. Assoc. Cancer Res., 36, 358.
  4. Newman, R. A. and T. Madden, 1995. Preclinical Pharmacology of Novel Rainforest-Derived Anti-HIV Compounds: Costatolide (NSC-661122), 7,8-Dihydrocostatolide (NSC-661123) and Calanolide A (NSC-664737), [Abstract No. 1858]. Proc. Amer. Assoc. Cancer Res., 36, 312.
  5. Page, J.G., L.E. Rodman, J.E. Heath, J.E. Tomaszewski and A.C. Smith, 1995. Effect of Infusion Rate on the Toxicity of Depsipeptide (NSC-630176) in Beagle Dogs. [Abstract No. 2193]. Proc. Amer. Assoc. Cancer Res., 36, 368.
  6. Placke, M.E., P.J. Tosca, R.M. Moutvic, J.T. Yarrington and J.E. Tomaszewski, 1995. Safety Studies of Three 13-Mer Point Mutated ras Peptides in Rabbits and Two Recombinant Point Mutated ras/Vaccinia Virus Constructs in Monkeys. [Abstract No. 2932]. Proc. Amer. Assoc. Cancer Res., 36, 492.
  7. Reid, J.M., D.L. Walker and M.M. Ames, 1995. Evaluation of L1210 Bioassay and HPLC Determination of Dolastatin 10 in Human and Murine Plasma, [Abstract No. 2171]. Proc. Amer. Assoc. Cancer Res., 36, 364.
  8. Rodman, L.E., J.E. Heath, J.M. Trang, R.D. Wood, J.E. Tomaszewski, A.C. Smith and J.G. Page, 1995. Preclinical Toxicology and Pharmacology Studies of BE4x4 (NSC-640506) in Beagle Dogs. [Abstract No. 2194]. Proc. Amer. Assoc. Cancer Res., 36, 368.
  9. Schindler-Horvat, J.E., J.C. Mirsalis, J.R. Hill, N. Raju, S.J. Donohue and C.A. Tyson, 1995. Preclinical Toxicology Studies of Quinocarmycin Analog DX-52-1, [Abstract No. 2188]. Proc. Amer. Assoc. Cancer Res., 36, 367.
  10. Schmid, S.M., R.T. Coffield, J.E. Harwell, D.G. Gordon, B.L. Osborn, J.E. Tomaszewski and J.G. Page, 1995. In Vitro Toxicity of Anti-HIV Dideoxynucleosides in Human and Rat Myocytes. [Abstract No. 2192]. Proc. Amer. Assoc. Cancer Res., 36, 368.
  11. Schweikart, K.M., R. Parchment, B. Osborn, M. Murphy, R. May, J. Page and J.E. Tomaszewski, 1995. In Vitro/In Vivo Bone Marrow Toxicity: Comparison of Clinical and Preclinical Data for Selected Anticancer Drugs. [Abstract No. 2185]. Proc. Amer. Assoc. Cancer Res., 36, 367.
  12. Tomaszewski, J.E., K.M. Schweikart, G.E. Wilkinson, S. Graves, C. Mahon, J. Toft, J. Yarrington and M.E. Placke, 1995. Preclinical Toxicity Evaluation of ß-F-ddA in the Rat and Dog. [Abstract No. 2184]. Proc. Amer. Assoc. Cancer Res., 36, 367.
  13. Volpe, D.A., J.E. Tomaszewski, R.E. Parchment, A. Garg, K.P. Flora, M.J. Murphy and C.K. Grieshaber, 1995. Myelotoxic Effects of Bizelesin to Human, Canine and Murine Myeloid Progenitor Cells. [Abstract No. 2182]. Proc. Amer. Assoc. Cancer Res., 36, 366.
  14. Walker, D.L., J.M. Reid and M.M. Ames, 1995. Preclinical Pharmacology of the HIV Protease Inhibitor, DG35 (NSC 654021), [Abstract No. 2170]. Proc. Amer. Assoc. Cancer Res., 36, 364.
  15. Wheeler, C.W., B.S. Levine, J. Kantor, J.E. Tomaszewski and S.J. Donohue, 1995. Safety and Immunogenicity of a Recombinant Vaccinia Virus Vaccine Expressing a 70kDa Fragment of the Human Carcinoembryonic Antigen in a Nonhuman Primate. [Abstract No. 2179]. Proc. Amer. Assoc. Cancer Res., 36, 366.
  16. Tomaszewski, J.E., 1995. Preclinical Toxicity of Ecteinascidin 743. Winter Meeting of the EORTC PAMM Group, Newcastle Upon Tyne, UK.

About the Branch Chief

For information regarding the TPB, please contact Dr. Jerry M. Collins, Associate Director, collinsje@mail.nih.gov